IRESS LIMITED — Director's Dealing 2020

Sep 1, 2020

==> picture [82 x 63] intentionally omitted <==

The Manager Company Announcements Office Australian Stock Exchange Exchange Centre 20 Bridge Street SYDNEY NSW 2000

2 September 2020

Dear Sir or Madam

RE: APPENDIX 3Y – ANDREW WALSH – CEO & MANAGING DIRECTOR

Please find attached an Appendix 3Y relating to the vesting of 2400 performance rights for Andrew Walsh, being additional vesting on retest of the 2016 grant and confirming that the remaining rights in the grant have lapsed.

In preparing the 3Y we have noticed and corrected a minor error in Andrew Walsh’s ‘indirect’ holdings. The previous 3Y from July listed ‘Salernes Pty Ltd ATF the Walsh Family Trust’ as holding 47,788 shares. A second minor holding for ‘Onlywho Pty Ltd ATF Walsh Family Superfund’ of 5683 shares was not noted, though a portion of that holding was included in the Salernes holding. The combined indirect holding is 49,541 as compared to the amount disclosed in July of 47,788.

That omission has been corrected in the attached 3Y.

Yours sincerely,

==> picture [156 x 67] intentionally omitted <==

Peter Ferguson Group General Counsel & Company Secretary

Iress Limited Corporate Office: Level 16, 385 Bourke Street MELBOURNE VIC 3000 Australia ABN: 47 060 313 359

T +61 3 9018 5800 enquiries@iress.com www.iress.com

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Iress Limited
ABN	47 060 313 359

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Andrew Walsh Date of last notice 15 July 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Date of change No. of securities held prior to change	Direct
	24 August 2020
	Ordinary Shares Direct: 494,580 Indirect: 47,788 542,368 Unvested Share/Rights Grants Overview: Deferred Share Rights all Series: 94,443 Performance Rights pre-2019 Series: 235,488 Unvested Rights/Grants under revised 2019 executive remuneration framework:

• See chapter 19 for defined terms.

15/07/2020Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Equity Rights: 156,394 Performance Rights: 160,936 Unvested Share/Rights Grants Details: 2016 Series subject to six month retest in June 2020 Performance Rights 2016: • 4 year term, granted May 2016, 3 year measurement period commencing 1 Jan 2017: - 22,800 • 4 year term, granted May 2016, 4 year measurement period commencing 1 Jan 2016: - 12,000 2017 Series Performance Rights 2017: • 4 year term, 3 year measurement period commencing 1 Jan 2018: - 54,739 • 4 year term, 4 year measurement period commencing 1 Jan 2017: - 54,739 2018 Series Deferred Shares Rights 2018: • 3 year term, granted 10 May 2018: - 51,707 Performance Rights 2018: • 4 year term, granted 10 May 2018, 3 year measurement period commencing 1 Jan 2019: - 45,605 • 4 year term, granted 10 May 2018, 4 year measurement period commencing 1 Jan 2018: - 45,605 2019 Series Deferred Shares Rights 2019: • 3 year term, granted 9 May 2019: - 42,736 2019 Series – New Framework Equity Rights 2019: • 2 year term, granted 9 May 2019: - 80,020 Performance Rights 2019: • 3 year term, granted 9 May 2019: – 80,020 2020 Series – New Framework Equity Rights 2020: • 2 year term, granted 21 May 2020, 2 year measurement period commencing 28 Feb 2020 – 28 Feb 2020, (shares provided on exercise of any vested Equity Rights are subject to a mandatory 2 year holding lock (28 February 2022 – 28 February 2024)): – 76,374 Performance Rights 2020: • 3 year term, granted 21 May 2020, 3 year measurement period commencing 1 Jan 2020 – 31 Dec 2022: – 80,916

Class

Ordinary

• See chapter 19 for defined terms.

15/07/2020Appendix 3Y Page 2

Appendix 3Y Change of Director’s Interest Notice

Number acquired		Ordinary Shares Direct: 2,400 Indirect: Nil
Number disposed		Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		$10.82 per share $25,968 in total
No. of securities held after change		Ordinary Shares Direct: 496,980 Indirect: 49,541 544,768 Unvested Share/Rights Grants Overview: Deferred Share Rights all Series: 94,443 Performance Rights pre-2019 Series: 233,088 Unvested Rights/Grants under revised 2019 executive remuneration framework: Equity Rights: 156,394 Performance Rights: 160,936 Unvested Share/Rights Grants Details: 2016 Series subject to six month retest in June 2020 Performance Rights 2016: • 4 year term, granted May 2016, 3 year measurement period commencing 1 Jan 2017: - 1200 vesting on retest, 21,600 lapsed. Balance = 0 • 4 year term, granted May 2016, 4 year measurement period commencing 1 Jan 2016: - 1200 vesting on retest, 10,800 lapsed. Balance = 0 2017 Series Performance Rights 2017: • 4 year term, 3 year measurement period commencing 1 Jan 2018: - 54,739 • 4 year term, 4 year measurement period commencing 1 Jan 2017: - 54,739 2018 Series Deferred Shares Rights 2018: • 3 year term, granted 10 May 2018: - 51,707 Performance Rights 2018:

• See chapter 19 for defined terms.

15/07/2020Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

• 4 year term, granted 10 May 2018, 3 year measurement period commencing 1 Jan 2019: - 45,605 • 4 year term, granted 10 May 2018, 4 year measurement period commencing 1 Jan 2018: - 45,605 2019 Series Deferred Shares Rights 2019: • 3 year term, granted 9 May 2019: - 42,736 2019 Series – New Framework Equity Rights 2019: • 2 year term, granted 9 May 2019: - 80,020 Performance Rights 2019: • 3 year term, granted 9 May 2019: – 80,020 2020 Series – New Framework Equity Rights 2020: • 2 year term, granted 21 May 2020, 2 year measurement period commencing 28 Feb 2020 – 28 Feb 2020, (shares provided on exercise of any vested Equity Rights are subject to a mandatory 2 year holding lock (28 February 2022 – 28 February 2024)): – 76,374 Performance Rights 2020: • 3 year term, granted 21 May 2020, 3 year measurement period commencing 1 Jan 2020 – 31 Dec 2022: – 80,916 Nature of change 2016 Performance Rights re-test Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

• See chapter 19 for defined terms.

15/07/2020Appendix 3Y Page 4

Appendix 3Y Change of Director’s Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

art 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

15/07/2020Appendix 3Y Page 5